ETH Zürich and collaborators at the University of Lyon and the University of Basel described ECHO, a wirelessly powered implant concept designed for drug-free metabolic control in a diabesity mouse model. The device uses electrocatalysis to remove excess glucose on demand, triggered when blood glucose crosses a preset threshold. In the preclinical results reported in Science Advances, treated mice restored elevated glucose toward normal ranges over repeated dosing periods while shifting metabolism toward fat use and reducing body weight. The system was coupled to a continuous glucose monitor through a smartphone to support closed-loop operation. The approach aims to reduce dependence on chronic medications by providing dynamic regulation of disease-relevant metabolites, addressing limitations seen with existing glucose-monitoring and insulin-delivery systems. The core translational question is whether the electrocatalytic specificity and control precision can be maintained in humans without safety or biocompatibility tradeoffs. If scaled successfully, ECHO-style devices could open a new category of metabolite-targeting interventions that function outside conventional drug pharmacology.